Chemistry: molecular biology and microbiology – Animal cell – per se ; composition thereof; process of...
Reexamination Certificate
1999-07-29
2001-09-25
Lankford, Jr., Leon B. (Department: 1651)
Chemistry: molecular biology and microbiology
Animal cell, per se ; composition thereof; process of...
C424S093700, C435S001100, C435S284100, C435S289100, C435S370000, C435S395000
Reexamination Certificate
active
06294380
ABSTRACT:
BACKGROUND OF THE INVENTION
1. Field of Invention
The present invention generally relates to a liver-assist device and liver cell clones which may find application in artificial liver systems, extracorporeal liver-assist devices and bioreactors. More particularly, the present invention is directed to a liver cell clone with enhanced detoxification activities. The liver cell clone is characterized as having increased GSH content and elevated GST activity as compared to conventional immortalized human hepatocyte cell lines and primary human hepatocyte cultures isolated from liver tissue.
2. Background of the Related Art
Over the past several years, the focus of investigations employing extracorporeal liver support systems for the treatment of fulminant liver failure and liver dysfunction has been shifting from basic experimentation and animal trials to clinical evaluations and applications. Some groups in the United States are conducting, under the supervision of the Food and Drug Administration, clinical trials with various bioartificial liver devices (See, e.g., Rozga J. et al., J. Ann. Surg. 219:538-46, 1994, Sussman N. L. et al., Amer. J. Kid. Dis. 18:371-84, 1996, Sussman N. L., Clin Invest. Med. 19:393-9, 1996, Dixit V., Scan. J. Gastroenterol. Suppl. 220:101-14, 1996). Similarly, several groups in Euro-Asia (in particular, Germany, the Netherlands, Great Britain, and Russia) have commenced pre-clinical trials into the effectiveness of bioartificial-liver devices in treating liver dysfunctions (See, e.g., Gerlach J., Transplant. Proc. 29:852, 1997, Hughes R. D et al., Semin. Liver Dis. 16:435-444, 1996). Research into bioartificial liver support devices is also quite active in Japan.
The immediate objective of temporary liver support (which may be provided by bioartifical-liver devices) is to maintain a patient with acute or fulminant hepatic failure or dysfunction until the patient's own liver regenerates. From the clinical data available, it appears that liver support systems are mainly used to bridge the patient to orthotopic transplantation, to improve cerebral circulation and to improve hemo-dynamic parameters.
Rozga and his group have reported on 19 patients treated with bioartificial liver (BAL) devices for 7-hour periods on one to five occasions. Two groups of patients were studied, eleven (11) with acute liver failure and eight (8) with chronic liver failure. Liver transplantation was performed at a mean of 39 hours after initiating BAL support. Thirteen (13) patients, all eleven (11) suffering from acute liver failure and two (2) of the chronic liver failure group, survived after liver transplantation. Patients who were not candidates for transplantation, and therefore did not receive a liver transplant, died (Kamlot A. and Rozga J., Biotech & Bioeng. 50:382-91, 1996).
In a clinical study carried out by Sussman et al. (Sussman N. L. et al., Amer. J. Kid. Dis. 18:371-84, 1996), eleven (11) patients with acute liver failure were treated with an extracorporeal liver assist device (ELAD) for up to 114 hours. Nine of ten patients in whom multiple estimations of galactose elimination capacity were measured showed improved galactose elimination capacity. One (1) patient recovered without transplantation, four (4) patients underwent transplantation, and the others died.
Only occasionally has treatment with bioartificial liver support systems, ELAD or BAL, alone been shown to lead to complete recovery (Sheil A. G. R. et al., Aust. N. Z. J. Surg. 66:547-52, 1996; Watanabe F. D. et al., Ann. Surg. 225:484-91, 1997). Further, although hepatocyte-based hybrid extracorporeal livier support devices have demonstrated significant improvement in metabolic functions in a variety of experimental and animal tests, such degree of improvement has been difficult to duplicate completely in humans. The efficiency of treatment demonstrated in human patients suffering from hepatic failure is not so striking as compared to the efficiency seen in animals, as shown in those patients who are treated with either of the two most widely used extracorporeal liver-assist systems. For example, a well-controlled clinical trial recently carried out in the U.K to assess the overall value of ELAD (Sussmann) and BAL (Rozga) in the treatment of patients suffering from hepatic dysfunction, showed that while the two systems enhanced certain metabolic functions in such patients, the magnitude of the enhancement was not at a desired level (Hughes R. D. et al., Semin. Liver Dis. 16:435-444, 1996). Similar studies suggest that the functional capacity of conventional extracoporeal liver-assist devices may be limited, particularly considering the number of metabolic functions needing correction in the fulminant patient.
Numerous obstacles have impeded the development of efficient extracorporeal liver-support devices for routine clinical application. These are: (1) an imperfect understanding of the basic pathophysiology of liver dysfunction, liver biology and the regulation of the proliferation of hepatocytes; (2) absence of knowledge in regard to the mechanisms involved in the development of hepatic coma and/or encephalopathy in fulminant hepatic failure; (3) an inability to produce, and maintain in a bioreactor, a sufficient number of hepatocytes with sufficient. bio-activity to correct failing liver functions in fulminant hepatic failure patients. At present, hepatocytes used in conventional extracorporeal liver-assist devices are typically harvested from primary liver cultures obtained from animals, particularly the pig, or consist of immortalized cells derived from humans. Fresh hepatocytes have the advantage of differentiated functionality, but lack proliferation ability. The situation is Just reverse in term of immortalized cells. These two types of hepatocytes are often at opposite ends of a biologic continuum.
As differentiation and proliferation are found to be incompatible in a large number of cell types (evidently in accord with some basic biological principle), it is often difficult to obtain large number of hepatocytes with desired multiple functionalities. Common BAL devices contain about 50 g primary cultures from pig liver, which is significantly lower than that physiologically minimal mass (ranging from 200-400 g) hypothesized to be needed for efficient metabolic activity. On the other hand, even ELAD devices employing as much as 400 g of C3A immortalized cells have provided insufficient major synthetic and metabolic functions (Hughes R D et al, Liver Transpl Surg 1:200-6, 1995). For example, Gailetti et al. conducted a study which ostensibly used adequate amounts of primary hepatocyte cultures in a complex and well-designed configuration, desirable function could only be found for a limited period of about 7 hours (Gailetti P. M. & Jauregui H. O., in Handbook of Bioengineering pp 1952-66, 1995).
At this time, continuous support of patients with fulminant hepatic failure appears to be impractical using fresh pig livers. Further, no method has been developed yet which adequately prevents hepatocytes from a human or porcine source from deteriorating in vitro. Although great efforts have been made to improve the performance of hepatocytes in such systems, including primary culture from xenograft and established cell lines, no report has claimed to maintain desired functions of differentiated hepatocytes for significant periods of time in bioartificial liver-support system bioreactors. Loss of hepatic functions in culture appears to be associated with cellular responses involving cellular interactions and cellular apoptosis in vitro (Collins B. H. et al., Transplantation 58:1162-71, 1994); Rivern D. J. et al. Transplant Proc. 31:671-73, 1999). It should be noted that cells isolated from the body are maintained in a non-physiologic environment and are cut off from numerous regulatory mechanisms which control hepatocyte function in vivo. It appears that the hepatocyte bioreactors for bioartificial liver support have reached their maximal performance at present, and that further improvement will no
Kazuo Izumi
Kimura Hajime
Klinkmann Horst
Qiang Shi
JMS Co. Ltd.
Lankford , Jr. Leon B.
Pillsbury & Winthrop LLP
LandOfFree
Liver cell clones for use in extracorporeal liver-assist device does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Liver cell clones for use in extracorporeal liver-assist device, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Liver cell clones for use in extracorporeal liver-assist device will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2443767